Continuous bioprocessing is often described as a sequence of intensified unit operations connected by material flow. That description is operationally useful but analytically incomplete because it does not explain how disturbances originating in cell culture are transformed, attenuated, amplified, or obscured before they appear as final product-quality variation. This Systems Perspective argues that continuous biomanufacturing should be controlled as a coupled, multiscale system in which observable process variables, latent cellular states, intermediate product states, downstream transformation states, and critical quality attributes remain analytically distinct. The central proposal is a quality-first control architecture that links upstream disturbance detection to state estimation, cross-unit propagation logic, quality-relevant observation, and recovery decisions without assuming that any single surrogate variable is sufficient. Evidence from integrated continuous antibody manufacturing, perfusion culture, downstream intensification, online quality monitoring, soft sensing, and model-based control shows that many components of such an architecture are technically feasible, but not yet validated as one unified control system. The proposed framework therefore emphasizes evidence boundaries, applicability domains, model uncertainty, and the need to distinguish process recovery from product-quality recovery. Continuous manufacturing can become more robust not merely by increasing automation, but by organizing automation around the causal and inferential distance between upstream variability and final product quality.
IJPRAS
